Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Person › Details

Mathias Winterhalter (Jacobs University Bremen, School of Engineering and Science)

Winterhalter, Mathias (Jacobs Univ Bremen 2009 Professor School of Engineering and Science)

 

Organisation Organisation Jacobs University Bremen, School of Engineering and Science
  Group Jacobs University Bremen gGmbH (JUB)
Product Product LIFE SCIENCES
     

European ScreeningPort GmbH. (6/4/13). "Press Release: European ScreeningPort Takes Up the Fight against Multiresistant Bacteria within a Joint IMI Research Initative". Hamburg.

European ScreeningPort is consortium partner of TRANSLOCATION, a project within the frame of the IMI Call6 - New Drugs for Bad Bugs (ND4BB)- programme


European ScreeningPort is pleased to announce that it is partner of an international consortium funded by the Innovative Medicine Initiative (IMI). The project "TRANSLOCATION" (Molecular basis of the bacterial cell wall permeability) is one of the first two projects funded under IMI's antimicrobial resistance (AMR) research programme, 'New Drugs for Bad Bugs' (ND4BB), set out to spur antibiotic development. The project addresses Topic 2, 'LEARNING FROM SUCCESS AND FAILURE & GETTING DRUGS INTO BAD BUGS' which was launched as part of IMI's 6th Call.

The TRANSLOCATION consortium is composed of 25 partners, (Pharmaceutical companies, universities, research institutes and SMEs) and is coordinated by GlaxoSmithKline and the Jacobs University, Bremen (http://www.imi.europa.eu/content/translocation).

TRANSLOCATION will focus its efforts on identifying new ways of getting antibiotics into bacteria and preventing bacteria from expelling the drugs before they can take effect. It will work primarily on drug resistant Gram-negative bacteria which are responsible for two thirds of the 25,000 deaths resulting from antimicrobial resistance reported in Europe annually.

A unique aspect of TRANSLOCATION is the setting up of an Information Centre to allow knowledge and data sharing, in order to increase efficiency in antibiotic R&D. The European ScreeningPort coleads the Work Packages covering the establishment and utilization of the ND4BB Information Centre. The goal will be to help create a data management system for the collection of historic and novel data on antibacterial research and provide tools for their systematic analysis.

"It is an exciting challenge to help establish the ND4BB Information Centre to support "learning from success and failure" in antibiotic research, and we are very proud to be a member of the TRANSLOCATION consortium. The aim of the ND4BB Information Centre is to improve efficiency in antibiotic pharmaceutical R&D by facilitating knowledge exchange across the Academic, Biotech and EFPIA partners, and IMI's public private partnership model is the ideal platform to make this goal a reality. There is much discussion about the impact of "Big Data" approaches on improving pharmaceutical R&D and we see this pioneering project as a concrete example of how advanced informatics approaches can be used to benefit human health." states Dr. Philip Gribbon, CSO/COO of European ScreeningPort GmbH.


About European ScreeningPort GmbH

European ScreeningPort, based in Hamburg, Germany is a public-private partnership, which works with academic institutes and universities across Europe. The company performs bioassay development and validation, primary screening of small molecules, high content screening for secondary and selectivity assays, bioinformatics and virtual screening for academic partners. The research leading to these results has received support from the Innovative Medicines Initiative under grant agreement n° 115525, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA) in kind contribution (www.imi.europa.eu).

Contact:

Dr. Mira Grättinger phone: +49 40 56081 470
European ScreeningPort GmbH fax: +49 40 56081 453
Schnackenburgallee 114 email: mira.graettinger@screeningport.com
D-22525 Hamburg web: www.screeningport.com

   
Record changed: 2017-04-09

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px



To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px




» top